Study of BH3120 with or without pembrolizumab for advanced cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, BH3120, alone or with pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the combination can help your immune system fight cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer (solid tumor) that has spread or cannot be removed, and standard treatments are no longer working.
- Your tumor tests positive for PD-L1 (a protein that helps cancer escape immune system attacks).
- You have at least one tumor that can be measured by scans and has not been treated with radiation.
- You are 18 years or older and can take care of yourself (able to work or do daily activities with little help).
- Your blood counts and liver function are good enough to safely receive the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.